Yellowbird Diagnostics Announces First Patients Dosed in Phase 1 Trial of NeuCaVis™

Yellowbird Diagnostics recently announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent designed to enable precise visualization of inflammation. NeuCaVis™ represents a new approach to imaging by targeting fructose metabolism, a key pathway associated with inflammatory activity. The technology has the potential to support earlier and more accurate detection of a broad range of serious conditions, including cardiovascular diseases, chronic inflammatory disorders, neuroinflammation, and cancer.

Yellowbird Diagnostics is an OBIO® member, alumnus of our CAAP® program, and presented at the OBIO® Investment Summit.